Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cystic Fibrosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cystic Fibrosis
    TopAbstracts in Cystic Fibrosis 06/30/2008 - (DGNews)
    TopAbstracts in Cystic Fibrosis 06/02/2008 - (DGNews)
    TopAbstracts in Cystic Fibrosis 05/05/2008 - (DGNews)
    TopAbstracts in Cystic Fibrosis 04/07/2008 - (DGNews)
    TopAbstracts in Cystic Fibrosis 03/10/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Cystic Fibrosis
      Diagnosis of Cystic Fibrosis
      Aggressive Treatment Strategies in the Fight Against Cystic Fibrosis
      Disease Managment Lessons of Cystic Fibrosis: Paradigms From an Orphan

      Webcasts/CME archive

       Recent cases - Cystic Fibrosis
        An Atypical Presentation of Cystic Fibrosis: A Case Report
        Cystic Fibrosis Presenting as Recurrent Pancreatitis in a Young Child with a Normal Sweat Test and Pancreas Divisum: A Case Report
        Extracorporeal Membrane Oxygenator as a Bridge to Successful Surgical Repair of Bronchopleural Fistula Following Bilateral Sequential Lung Transplantation; A Case Report and Review of Literature
        Cystic Fibrosis and Renal Disease: A Case Report
        Inhaled Tobramycin Solution-Associated Recurrent Eosinophilia and Severe Persistent Bronchospasm in a Patient with Cystic Fibrosis: A Case Report

        Cases archive
          




        my personal edition > cystic fibrosis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Azithromycin Promising In Cystic Fibrosis Treatment

        Lancet

        09/26/2002
        By Harvey McConnell


        The macrolide antibiotic azithromycin can offer some benefit to people with cystic fibrosis who do not respond to conventional treatment.

        Since azithromycin has anti-inflammatory properties potentially beneficial in cystic fibrosis, and open pilot studies indicate a clinical benefit, a formal trial was undertaken by Dr Mark Rosenthal and colleagues at the Royal Brompton Hospital, London, England.

        Forty one children with cystic fibrosis between the ages of eight and 18 years were enrolled in a 15-month randomised double-blind, placebo-controlled crossover trial. They had a median forced expiratory volume in 1 s (FEV1 ) of 61 percent, with a range of 33 to 80 percent.

        The children received either azithromycin (bodyweight 40 kg: 250 mg daily, >40 kg: 500 mg daily) or placebo for six months. After two months of washout, the treatments were crossed over.

        The clinicians point out that as 95 percent of patients ultimately die of respiratory failure, a major aim is to treat endobronchial infection and inflammation. A narrow range of organisms, including Staphylococcus aureus and mucoid Pseudomonas aeruginosa, cause infections, and P aeruginosa is almost exclusively seen in patients with cystic fibrosis. Whether inflammation precedes infection or is exaggerated in response to it is uncertain.

        Clinicians found in the trial that children given azithromycin had a modest improvement in FEV1 of 5.4 percent. However, there was wide variation, with 13 children improving and five children deteriorating by 13 percent. Forced vital capacity and mid-expiratory flow did not significantly change overall.

        There was no difference in quality-of-life assessment between azithromycin and placebo groups. The antibiotic was well tolerated with few reported side effects.

        Dr Rosenthal and colleagues conclude: "A four to six month trial of azithromycin is safe, comparatively inexpensive, and could greatly benefit the lung function of patients who do not respond adequately to conventional treatment for cystic fibrosis. The mechanism of benefit remains unknown."
        Lancet 2002; 360: 978-84.

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send